ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0562

Large-Scale Targeted Sequencing Study Links Systemic Juvenile Idiopathic Arthritis with Rare Variants of MEFV, LYST, STXBP2, UNC13D
Abstract Number: 1402

Late Onset Rheumatoid Arthritis Has a Similar Remission Rate as Younger Onset Rheumatoid Arthritis: Results from an Ontario Rheumatoid Arthritis Registry
Abstract Number: 1482

Latent Tuberculosis Infection and Its Associations with Clinical and Serological Parameters in Systemic Lupus Erythematosus
Abstract Number: 1456

Latin-American Systemic Lupus Erythematosus Clusters
Abstract Number: 0202

Learning Needs Assessment for Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors
Abstract Number: PP08

Learning to Advocate for Myself and the Young Adult Community While Finding My Place as a Patient Partner at CARRA (Childhood Arthritis and Rheumatology Research Alliance)
Abstract Number: 1862

Lenabasum Reduces IFNγ and pIRF3 in Dermatomyositis Skin: Biomarker Results from a Double-Blind Phase 3 International Randomized Controlled Trial
Abstract Number: 1860

Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Activates Diverse Cell-specific Pathways in Whole Blood Leukocytes in Dermatomyositis
Abstract Number: 0161

Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Exerts Anti-Inflammatory Effects in Dermatomyositis in Th1 Cells
Abstract Number: 1281

Less Than Half of Cryoglobulin Tests Ordered at a Tertiary Hospital Network Are Successfully Completed: An Opportunity for Improvement
Abstract Number: 0824

Lessons Learned from a Cohort of Adult Afro-Caribbean Patients Diagnosed Clinically with Dermatomyositis
Abstract Number: 1698

LINE1 Reverse Transcriptase Inhibitors Abrogate Type 1 Interferon Responses
Abstract Number: 0226

Linguistics Biases in Letters of Recommendation Written for Rheumatology Fellowship Applicants
Abstract Number: 2163

Lipid Profile in Scleroderma Patients and the Associations of Its Changes with Disease-specific Features
Abstract Number: 1963

Lipid Screening and Statin Use in Rheumatoid Arthritis Patients in an Underserved Population

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].